

# Woori Financial Group (316140.KS): 1025 Review: Earnings below expectations but strengthens CE1 ratio; Neutral

#### Earnings below expectations on higher cost and additional provisioning

Woori reported 1Q25 net profit of W616bn, missing our and Bloomberg consensus estimates by -6%/-17%. Despite a sizable NIM expansion and solid non-interest income trends, earnings weakened due to increased investments (i.e., brokerage subsidiary & digital), ERP cost carry-over and additional provisioning on HomePlus and construction completion guarantees. By slowing growth, the group CET1 ratio improved by 30bp to 12.4% and W250 quarterly DPS (+11% y-o-y) was announced.

Sinyoung Park +82(2)3788-1778 | sinyoung.park@gs.com Goldman Sachs (Asia) L.L.C., Seoul Branch

#### CET1 ratio strengthened to 12.42% (vs. 12.5% year-end target)

With CET1 ratio enhancement as key priority, the group again stepped back in lending (-1% q-o-q) and focused on group-wide asset re-balancing. While the group plans to partially resume RWA growth in the coming quarters, management intention to exceed 12.5% is clear given tiered-TSR framework (up to 35%/40% TSR within 12.5%/13.0% CET1 ratio range). With CET1 ratio trajectory improving, we raise our 2025ETSR ratio expectation to 38% (vs. 35% previously).

### Still waiting on the regulatory approval for life insurance subsidiaries' integration

While the regulatory approval for TongYang and ABL Life insurance acquisition is still pending and may get delayed to early May to conduct further due diligence, management continued to highlight that integrating life insurers will have limited impact on CET1 ratio but will push up non-bank profit contribution and ROE by 10%pt/c1%pt and allow for a faster uplift in both CET1 and TSR ratios.

#### Keeping Neutral given relative outperformance and lower TSR expectation

Following 1Q result, we fine-tune our 2025E-27E estimates and keep our TP unchanged at W17,000. Still, we are Neutral rated as we think the absolute level of TSR will likely lag peers given a weaker capital position and given relative outperformance since Oct24 (+12% vs. KB/Shinhan/Hana). We think adding non-bank operations could help lift ROE and enhance CET1 ratio, but we wait for the regulator approval on subsidiary inclusion for Tong Yang & ABL Life acquisition. As per our risks section, a successful inorganic growth strategy could pose upside risk to earnings and the share price and could cause us to revisit our thesis.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to <a href="https://www.gs.com/research/hedge.html">www.gs.com/research/hedge.html</a>. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

Exhibit 1: Earnings below expectations on higher cost and additional provisioning Quarterly result summary for Woori FG  $\,$ 

(Wbn, %)

Income Statement	1Q24	2Q24	3Q24	4Q24	1Q25	qoq chg %	yoy chg %
Operating revenue	2,549	2,732	2,712	2,448	2,610	6.6%	2.4%
Net interest income	2,198	2,197	2,219	2,272	2,252	-0.9%	2.4%
Non-interest income	351	535	493	176	358	103.4%	2.0%
Fee & commission income	503	555	529	499	511	2.4%	1.7%
Trading income	235	312	313	121	286	137.1%	21.7%
Other income	(387)	(333)	(349)	(444)	(440)	0.9%	-13.6%
SG&A	1,032	1,069	1,057	1,311	1,306	-0.4%	26.6%
PPOP	1,517	1,662	1,655	1,137	1,303	14.7%	-14.1%
Loan Loss Provision	367	409	478	463	436	-5.8%	18.8%
OP	1,151	1,253	1,177	674	868	28.7%	-24.6%
Non-Operating Income	(7)	(6)	24	(43)	(5)	89.1%	30.7%
PRETAX INCOME	1,144	1,247	1,201	631	863	36.7%	-24.5%
Taxes	305	285	284	177	210	18.3%	-31.3%
NET PROFIT	839	962	917	454	654	43.9%	-22.1%
Minority interest	14.9	30.0	12.6	27.9	37.9	35.5%	153.9%
NP (Controlling)	824	931	904	426	616	44.5%	-25.3%
Pref/hybrid dividends	35	40	44	40	40	0.0%	n.m.
Attributable NP	789	892	860	386	576	49.0%	-27.0%
One-offs	(39)	(12)	(30)	(204)	(247)	n.m.	-533.3%
Normalized NP	852	940	926	574	795	38.4%	-6.8%

1Q25 (GSe)	diff (amt)	diff (%)
2,597	12.6	0.5%
2,204	47.8	2.2%
393	(35.2)	-9.0%
546	(34.2)	-6.3%
221	65.0	29.4%
(374)	(66.0)	-17.6%
1,298	7.9	0.6%
1,299	4.7	0.4%
385	50.5	13.1%
914	(45.8)	-5.0%
0	(4.7)	#DIV/0!
914	(50.5)	-5.5%
242	(32.5)	-13.4%
672	(18.1)	-2.7%
14.9	23.0	153.9%
657	(41.0)	-6.2%
39.2	42.2%	1.1%
617	(41.4)	-6.7%

Key ratios (%, bps)	1Q24	2Q24	3Q24	4Q24	1Q25	qoq chg %	yoy chg %
KRW loan growth (qoq)	1.0%	1.8%	5.2%	-2.2%	-0.9%	1.3%	-2.0%
KRW deposit growth (qoq)	1.0%	0.9%	5.5%	-4.2%	1.9%	6.1%	0.9%
LDR (KRW)	97.2%	97.8%	98.8%	97.7%	97.8%	0.1%	0.6%
NIM (Group, qtrly)	1.74%	1.74%	1.67%	1.66%	1.70%	0.04%	-0.04%
NIM (Bank, qtrly)	1.50%	1.47%	1.40%	1.40%	1.44%	0.04%	-0.06%
NIS (Bank, qtrly)	1.46%	1.45%	1.43%	1.41%	1.41%	0.00%	-0.05%
Cost-income ratio	40.5%	39.1%	39.0%	53.6%	50.1%	-3.5%	9.6%
Credit cost	0.40%	0.44%	0.49%	0.47%	0.45%	-0.02%	0.05%
NPL ratio %	0.45%	0.56%	0.55%	0.57%	0.69%	0.12%	0.24%
NPL coverage %	187%	150%	152%	153%	133%	-20.2%	-54.2%
Delinquency %	0.29%	0.32%	0.32%	0.32%	0.40%	0.07%	0.10%
ROA	0.63%	0.70%	0.65%	0.29%	0.44%	0.15%	-0.19%
ROE	11.2%	12.5%	11.7%	5.1%	7.6%	2.5%	-3.6%
CET1 %	12.0%	12.0%	11.9%	12.13%	12.42%	0.29%	0.47%

1Q25 (GSe)	diff (%)
-0.5%	-0.4%
0.0%	1.9%
97.6%	0.2%
1.67%	0.03%
1.41%	0.03%
0.0%	1.4%
50.0%	0.1%
0.40%	0.05%
0.57%	0.12%
163%	-30.8%
0.38%	0.02%
0.47%	-0.04%
8.1%	-0.5%
12.3%	0.1%

Source: Company data, Goldman Sachs Global Investment Research

26 April 2025 2

Exhibit 2: 1025 results comparison for Korea banks

	(Wbn, %, bps)	KB FG	Shinhan FG	Hana FG	Woori FG
	Net income	1,697	1,488	1,128	616
	Net income vs. consensus (standard)	7%	3%	8%	-17%
	PPOP growth, % y-o-y	6%	-3%	-2%	-149
	Net profit growth, % y-o-y	63%	13%	9%	-25%
Margin	Group NIM, %	2.01%	1.91%	1.69%	1.70%
-	NIM change, q-o-q (bp)	3bp	4bp	0bp	4b <sub>p</sub>
	NIM change, y-o-y (bp)	-10bp	-9bp	-8bp	-4b <sub>l</sub>
	Bank NIM, %	1.76%	1.55%	1.48%	1.44%
	NIM change, q-o-q (bp)	4bp	3bp	2bp	4b <sub>j</sub>
	NIM change, y-o-y (bp)	-11bp	-9bp	-7bp	-6b <sub>j</sub>
	NIS change, q-o-q (bp)	4bp	4bp	2bp	0bp
	NIS change, y-o-y (bp)	-10bp	-25bp	-6bp	-5bp
Asset Quality	NPL ratio, %	0.76%	0.81%	0.70%	0.69%
	NPL ratio change, q-o-q (%pt)	0.11%	0.10%	0.09%	0.12%
	Coverage ratio, %	133.1%	128.8%	115.2%	132.79
	Coverage ratio change, q-o-q (%pt)	-17.8%	-14.1%	-13.5%	-20.29
	Credit costs, %	0.56%	0.41%	0.29%	0.45
	Credit costs, q-o-q (bp)	7bp	-26bp	-17bp	-2b
	Credit costs, y-o-y (bp)	17bp	3bp	2bp	5b
	Loan loss reserve, %	1.01%	1.04%	0.81%	0.919
	Loan loss reserve, q-o-q (%pt)	0.03%	0.02%	0.01%	0.04%
	Delinquency ratio, %	0.37%	0.37%	0.35%	0.409
	Overdue 30D+ ratio, q-o-q (%pt)	0.06%	0.07%	0.02%	0.079
	Overdue 30D+ loans, % q-o-q	21.3%	24.8%	5.9%	21.39
Capital	BIS ratio, %	16.6%	16.0%	15.7%	15.79
	BIS ratio change, q-o-q (bp)	14bp	18bp	9bp	3b
	CET ratio, %	13.7%	13.3%	13.2%	12.49
	CET ratio change, q-o-q (bp)	15bp	22bp	9bp	29b
	Tier-1 capital ratio, %	15.4%	15.0%	14.9%	14.39
	Tier-1 capital ratio change, q-o-q (bp)	25bp	27bp	22bp	11b
TSR	(T+1) Cash dividend (W bn)	335	281	250	149
	(T+1) Buyback (W bn)	364	317	117	50
	TSR run-rate (as % of FY TSR GSe)	27%	28%	24%	199
BS growth	KRW loan growth, % y-o-y	6.8%	7.5%	2.5%	3.89
· ·	KRW loan growth, % q-o-q	0.9%	0.1%	0.4%	-0.99
	KRW deposit growth, % y-o-y	-3.8%	-3.2%	-4.1%	0.99
	KRW deposit growth, % q-o-q	-1.9%	-0.8%	-3.2%	6.19
Others	Net interest income growth, y-o-y	2.9%	1.4%	2.3%	2.49
	Net interest income growth, q-o-q	0.6%	-1.9%	4.1%	-0.99
	Fee income % growth, y-o-y	-5.7%	-3.6%	1.7%	1.79
	Effective tax rate. %	26.3%	24.4%	25.9%	24.39
	(KRW) Loans / Deposits ratio, %	98.5%	95.8%	98.7%	97.89
	Cost / Income ratio, %	35.3%	37.3%	38.9%	50.19

Source: Company data

#### Valuation and risks

Following 1Q result, we fine-tune our 2025E-27E estimates and keep our TP unchanged at W17,000. Our 12-month target price is based on a target P/B multiple of 0.39x (was 0.38x) derived using the Gordon Growth Model. Still, we are Neutral rated as we think the absolute level of TSR will likely lag peers given a weaker capital position and given relative outperformance since Oct24 (+12% vs. KB/Shinhan/Hana). We think adding non-bank operations could help lift ROE and enhance CET1 ratio, but we wait for the regulator approval on subsidiary inclusion for Tong Yang & ABL Life acquisition. As per our risks section, a successful inorganic growth strategy could pose upside risk to earnings and the share price and could cause us to revisit our thesis.

Goldman Sachs

**Exhibit 3: Summary financials for WFG** 

Profit model (Wbn)	2023A	2024A	2025E	2026E	2027E	Balance sheet (Wbn)	2023A	2024A	2025E	2026E	2027
Operating revenue	9,837	10,440	10,681	10,649	10,930	244.135 3.1331 (172.1)	202071				
Net interest income	8,743	8,886	9,028	8,971	9,163	Gross loans	373,148	398,472	423,154	433,495	444,44
Non-interest income	1,095	1,554	1,654	1,678	1,767	NPLs	1,357	2,211	2,777	2,902	3,035
Fee income	1,720	2,086	2,250	2,362	2,481	Loan loss reserves	2,986	3,382	4,109	4,693	5,343
Other income	(626)	(532)	(596)	(684)	(714)	Total interest earning assets	465,313	494,896	518,125	529,770	542,083
SG&A expenses	4,443	4,469	4,932	4,810	4,955	Other non-interest earning assets	32,692	30,858	29,539	30,045	30,560
Preprovision ops profits	5,394	5,971	5,749	5,839	5,975	Total assets	498,005	525,753	547,665	559,815	572,643
Core preprovision ops profits	6,020	6,504	6,346	6,523	6,689	Customer deposits	357,784	367,295	378,908	386,776	395,075
Total provision charge	1,895	1,716	1,601	1,288	1,320	Total interest-bearing liabilities	430,010	445,619	458,820	468,641	479,007
Non operating gains	18	(32)	(5)	-	-	Total equity	33,397	35,895	37,229	39,661	42,136
Pretax profit	3,517	4,223	4,144	4,551	4,656	. our oquity	00,001	00,000	0.,0	00,00	-12,100
Core pretax profit	4,125	4,787	4,745	5,235	5,369	CAMEL RATIOS (%)	2023A	2024A	2025E	2026E	2027
Tax	891	1,051	1,079	1,206	1,234	C: Tier 1 capital ratio	12.0	12.1	12.6	13.0	13.
Minorities	121	85	81	72	87	C: Equity/loans	9.0	9.0	8.8	9.1	9.
Net profits	2,506	3,086	2,984	3,273	3,335	C: Equity/assets	6.7	6.8	6.8	7.1	7.
Dividends	747	891	896	985	1,034	A: NPL ratio	0.37	0.57	0.70	0.71	0.7
Dividends payout (%)	29.8	28.9	30.0	30.1	31.0	A: Loan loss reserves/NPLs	220.07	152.95	147.98	161.71	176.0
Dividends payout (76)	20.0	20.5	00.0	00.1	01.0	E: Net interest margin	1.82	1.70	1.68	1.62	1.6
Earnings Growth Drivers (%)	2023A	2024A	2025E	2026E	2027E	E: Non int inc/oper revenues	11.1	14.9	15.5	15.8	16.
Net interest margin	1.82	1.70	1.68	1.62	1.60	E: Cost-income ratio	45.2	42.8	46.2	45.2	45.3
Provision charge/ total loans	0.53	0.45	0.41	0.32	0.32	E: ROAA	0.49	0.57	0.53	0.56	0.5
YoY GROWTH (%)	0.55	0.43	0.41	0.52	0.52	L: Loan/deposit ratio (KRW)	98.7	97.7	98.3	98.6	99.0
Customer deposits	4.6	2.7	3.2	2.1	2.1	L. Loan/deposit fatto (KKW)	96.7	91.1	90.3	90.0	99.0
Loans (KRW)	5.5	5.8	2.4	2.4	2.5	Valuation (current price)	2023A	2024A	2025E	2026E	2027
Operating revenues	-0.1	6.1	2.4	-0.3	2.6	valuation (current price)	2023A	2024A	2023L	2020L	20271
Net interest income	0.5	1.6	1.6	-0.6	2.0	P/E - basic (X)	5.0	4.2	4.3	3.8	3.1
Non-interest income	-4.7	41.9	6.4	1.5	5.3	P/B (X)	0.46	0.42	0.39	0.36	0.33
Fee income	0.6	21.3	7.8	5.0	5.0	P/PPOP (X)	2.3	2.2	2.2	2.2	2.
Other income	-11.5	15.0	-12.1	-14.7	-4.3	Dividend yield (%)	5.8	6.9	7.1	8.0	8.1
SG&A expenses	-1.9	0.6	10.4	-2.5	3.0	Dividend yield (70)	3.0	0.5	7.1	0.0	0
Preprovision operating profits	1.5	10.7	-3.7	1.6	2.3	EPS	3,438	4,151	4,057	4,510	4,676
Core preprovision operating profits	2.4	8.0	-3.7 - <b>2.4</b>	2.8	2.5	PPOPPS	7,390	8,034	7,815	8,046	8,379
Provision charges	114.0	-9.4	-6.7	-19.6	2.5	BPS	37,313	40,788	43,926	48,516	53,732
Pretax profit	114.0	-5.4	-0.7	-15.0	2.5	Tangible BPS	36,795	39,385	42,070	45,964	50,168
Core pretax profit	-21.6	20.1	-1.9	9.8	2.3	DPS	1,000	1,200	1,220	1,380	1,500
NPAT	-17.4	16.1	-0.9	10.3	2.6	DF3	1,000	1,200	1,220	1,360	1,500
NEAT	-17.4	10.1	-0.9	10.3	2.0						
DuPont analysis	2023A	2024A	2025E	2026E	2027E	Market dimensions (bank only)	2023A	2024A	2025E	2026E	2027
ROE	8.8	10.0	9.1	9.4	9.0	No of branches	740	715	715	715	71
x leverage	18.2	17.5	17.2	16.7	15.9	No of staff	12,868	13,269	13,269	13,269	13,269
= ROA	0.49	0.57	0.53	0.56	0.56	Revenues/staff	258	307	286	279	292
						Net profits/staff	195	229	208	199	208
% of assets											
Net interest income	1.8	1.7	1.7	1.6	1.6						
Net non-interest income	0.2	0.3	0.3	0.3	0.3						
Operating revenues	2.0	2.0	2.0	1.9	1.9						
SG&A	(0.9)	(0.9)	(0.9)	(0.9)	(0.9)						
PPOP	1.1	1.2	1.1	1.1	1.1						
Loan loss provisions	(0.4)	(0.3)	(0.3)	(0.2)	(0.2)						
Net non-op income	0.0	0.0	0.0	0.0	0.0						
Pretax profits	0.7	0.8	0.8	0.8	0.8						
Taxes	(0.2)	(0.2)	(0.2)	(0.2)	(0.2)						
	(/	(/	(/	()	()	Note: Per share items are sum of quarte	erly numbers				
						, and an analysis of the second					

Source: Company data, Goldman Sachs Global Investment Research

#### **Price Target Risks and Methodology - Woori Financial Group**

Our 12m TP of W17,000 is based on a target P/B multiple of 0.39X, derived using the GGM formula [(ROE-g)/(COE-g)]. Upside risk: (1) Successful inorganic growth strategy could be an upside risk to earnings and the share price; (2) Stronger-than-expected economic turnaround, leading to lower-than-expected preemptive provisioning. Downside risk: (1) Overhang risk from strategic or financial investors given that the lock-up period is over. (2) Execution risks in potential M&A of non-bank entities, and

dilutive M&A could depress earnings as well as valuations.

316140.KS	12m Pri	ce Target: <b>W17,000</b>	Price: <b>W17</b> ,	300	Downside	: 1.7%
Neutral		GS Forecast				
			12/24	12/25E	12/26E	12/27E
Market cap: W1:	2.5tr / \$8.7bn	Net inc. (W bn) New	3,086.0	2,983.8	3,273.4	3,334.7
3m ADTV: W31.4	bn / \$21.7mn	Net inc. (W bn) Old	3,086.0	2,988.4	3,281.4	3,330.8
	South Korea	EPS (W) New	4,151	4,057	4,510	4,676
	rea Financials	EPS (W) Old	4,151	4,064	4,526	4,679
	M&A Rank: 3	EPS growth (%)	20.7	(2.3)	11.2	3.7
		P/E (X)	3.6	4.3	3.8	3.7
		P/B (X)	0.3	0.4	0.3	0.3
		Price/PPOP (X)	2.1	2.2	2.1	2.1
		Dividend yield (%)	8.0	7.1	8.0	8.7
			3/25	6/25E	9/25E	12/25E
		EPS (W)	845	1,209	1,218	822

Source: Company data, Goldman Sachs Research estimates, FactSet. Price as of 25 Apr 2025 close.

## Disclosure Appendix

#### Reg AC

I, Sinyoung Park, hereby certify that all of the views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

#### **GS Factor Profile**

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

**Growth** is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

#### M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

#### Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

#### **Disclosures**

The rating(s) for Woori Financial Group is/are relative to the other companies in its/their coverage universe: BNK Financial Group, DB Insurance Co., DGB Financial Group, Hana Financial Group, Hanwha Life Insurance, Hyundai M&F, Industrial Bank of Korea, KB Financial Group, KakaoBank Corp., Kakaopay Corp, Meritz Financial Group, Samsung F&M, Samsung Life Insurance, Shinhan Financial Group, Woori Financial Group

#### **Company-specific regulatory disclosures**

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs has received compensation for investment banking services in the past 12 months: Woori Financial Group (W17,300)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: Woori Financial Group (W17.300)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: Woori Financial Group (W17,300)

Goldman Sachs had a non-investment banking securities-related services client relationship during the past 12 months with: Woori Financial Group (W17.300)

Goldman Sachs had a non-securities services client relationship during the past 12 months with: Woori Financial Group (W17,300)

Goldman Sachs makes a market in the securities or derivatives thereof: Woori Financial Group (W17,300)


#### Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe

	F	Rating Distribution	n	Investme	ent Banking Relat	ionships
	Buy	Hold	Sell	Buy	Hold	Sell
Global	49%	34%	17%	 63%	57%	42%

As of April 1, 2025, Goldman Sachs Global Investment Research had investment ratings on 3,016 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

#### Price target and rating history chart(s)



may not have included price targets, as well as developments relating to the company, its industry and financial markets

#### Target price history table(s) Woori Financial Group (316140.KS)

Date of report	larget price (W
07-Feb-25	17,000
13-Jan-25	16,700
25-Jul-24	16,800
03-Jul-24	16,300
26-Apr-24	16,500
10-Mar-24	17,000
06-Feb-24	13,000
13-Jul-23	12,000

### Regulatory disclosures

#### Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

**Distribution of ratings:** See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <a href="https://www.gs.com/research/hedge.html">https://www.gs.com/research/hedge.html</a>.

#### Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. Australia: Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Brazil: Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. Canada: This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities

and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. Hong Kong: Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SÉBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at this link: https://publishing.gs.com/disclosures/hedge.html - /general/equity. Japan: See below. Korea: This research, and any access to it, is intended only for 'professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Russia: Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. Singapore: Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union and United Kingdom:** Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <a href="https://www.gs.com/disclosures/europeanpolicy.html">https://www.gs.com/disclosures/europeanpolicy.html</a> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, The Investment Trusts Association, Japan, and Japan Investment Advisers Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

#### Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks

**Total return potential** represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

**Coverage Universe:** A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at <a href="https://www.gs.com/research/hedge.html">https://www.gs.com/research/hedge.html</a>.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. Early-Stage Biotech (ES). An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company neither has a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. Rating Suspended (RS). Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not cover this company.

#### **Global product; distributing entities**

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the

Goldman Sachs

United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland and the Republic of Ireland; GSI - Succursale de Paris (Paris branch) which is authorised by the French Autorité de contrôle prudentiel et de resolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de resolution and the Autorité des marches financiers ("AMF") disseminates research in France; GSI - Sucursal en España (Madrid branch) authorized in Spain by the Comisión Nacional del Mercado de Valores disseminates research in the Kingdom of Spain; GSI - Sweden Bankfilial (Stockholm branch) is authorized by the SFSA as a "third country branch" in accordance with Chapter 4. Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and those jurisdictions within the European Economic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Succursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Succursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinpektionen) disseminates research in the Kingdom of Sweden.

#### **General disclosures**

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<a href="https://www.sipc.org">https://www.sipc.org</a>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <a href="https://www.theocc.com/about/publications/character-risks.jsp">https://www.theocc.com/about/publications/character-risks.jsp</a> and <a href="https://www.theocc.com/about/publications/character-risks.jsp">https://www.theocc.com/about/publications/character-risks.jsp</a> and <a href="https://www.theocc.com/about/publications/character-risks.jsp">https://www.theocc.com/about/publications/character-risks.jsp</a> and <a href="https://www.theocc.com/about/publications/character-risks.jsp</a> and <a href="https://www.theocc.com/about/publications/charac

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <a href="https://research.gs.com">https://research.gs.com</a>.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY

**Goldman Sachs** 

10282.

#### © 2025 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.

26 April 2025